🔎 Trials Near Me

Hjem › Overvekt › Nevada › Las Vegas

Kliniske studier for Overvekt i Las Vegas, NV

23 studier for Overvekt søker deltakere på steder i og rundt Las Vegas (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.

Offisiell studietekst (engelsk)

Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

RekruttererFase 2
  • Vector Clinical Trials /ID# 282265, Las Vegas
Alder 18 til 75 · Alle kjønn · Oppdatert 2. okt. 2026 · NCT07752979

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

RekruttererFase 3
  • Palm Research Center Inc., Las Vegas
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07720271

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

RekruttererFase 3
  • M3 Wake Research - Las Vegas Cimarron, Las Vegas
Alder 18 og eldre · Alle kjønn · Oppdatert 28. sep. 2026 · NCT07794579

A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight

RekruttererFase 3
  • Palm Research Center Tenaya, Las Vegas
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07369011

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

RekruttererFase 3
  • Excel Clinical Research, Las Vegas
  • Vector Clinical Trials, Las Vegas
Alder 45 til 99 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07037433

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

RekruttererFase 3
  • AMR Clinical, Las Vegas
Alder 18 og eldre · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07321886

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

RekruttererFase 2
  • Las Vegas Medical Research, Las Vegas
Alder 18 til 75 · Alle kjønn · Oppdatert 22. sep. 2026 · NCT07589608

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities

RekruttererFase 3
  • AURORA-1 Clinical Site, Las Vegas
Alder 18 og eldre · Alle kjønn · Oppdatert 16. sep. 2026 · NCT07743463

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

RekruttererFase 3
  • AURORA-2 Clinical Site, Las Vegas
Alder 18 og eldre · Alle kjønn · Oppdatert 16. sep. 2026 · NCT07743450

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

RekruttererFase 3Frivillige helsepersonell ønskes velkommen
  • ACCOMPLISH-2 Research Site, Las Vegas
Alder 18 til 79 · Alle kjønn · Oppdatert 11. sep. 2026 · NCT07654374

Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

RekruttererFase 3
  • Jubilee Clinical Research, Inc., Las Vegas
Alder 18 og eldre · Alle kjønn · Oppdatert 9. sep. 2026 · NCT07770841

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

RekruttererFase 2
  • Las Vegas Medical Research, Las Vegas
Alder 18 til 75 · Alle kjønn · Oppdatert 8. sep. 2026 · NCT06143956

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

RekruttererFase 2
  • Vector Clinical Trials, Las Vegas
Alder 18 til 75 · Alle kjønn · Oppdatert 8. sep. 2026 · NCT07215559

Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes

RekruttererFase 3
  • Kailera Clinical Site, Las Vegas
Alder 18 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT07284901

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

RekruttererFase 3
  • Palm Research Center Inc, Las Vegas
  • Vector Clinical Trials, Las Vegas
Alder 18 til 99 · Alle kjønn · Oppdatert 3. sep. 2026 · NCT07684235

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

RekruttererFase 3
  • Kailera Clinical Site, Las Vegas
Alder 18 og eldre · Alle kjønn · Oppdatert 3. sep. 2026 · NCT07284875

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)

RekruttererFase 3
  • Palm Research Center Inc, Las Vegas
Alder 18 til 99 · Alle kjønn · Oppdatert 3. sep. 2026 · NCT07684144

Assess the Effects of Replacing Foods High in Refined Carbohydrates With Avocado on Biomarkers of Inflammation.

RekruttererFrivillige helsepersonell ønskes velkommen
  • University of Nevada, Las Vegas, Las Vegas
Alder 21 til 74 · Alle kjønn · Oppdatert 27. aug. 2026 · NCT07566325

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

RekruttererFase 3
  • Research Site, Las Vegas
Alder 18 og eldre · Alle kjønn · Oppdatert 25. aug. 2026 · NCT07784725

Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)

RekruttererFase 3
  • ACCOMPLISH-1 Research Site, Las Vegas
Alder 18 til 79 · Alle kjønn · Oppdatert 10. aug. 2026 · NCT07654361

A Study to Evaluate the Safety and Tolerability of Different Doses of CX11 Tablets

RekruttererFase 1
  • Corxel Investigational site, Las Vegas
Alder 18 til 55 · Kvinner · Oppdatert 17. jun. 2026 · NCT07652047

Overvekt-studier i andre byer

Andre studier i Las Vegas

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.